OverviewPart 4 is titled "The Shadow of Gold." By the end of Part 3, the Low Countries (Dutch) Company had spread its net ...
This article is a Japanese translation of the article from the official Zimperium blog.Original publication date: April 16, ...
Panelists discuss insights from the MARIPOSA study on first-line treatment options for EGFR-mutant metastatic non–small cell lung cancer (NSCLC), highlighting the efficacy of amivantamab-lazertinib ...
Panelists discuss how the treatment landscape for EGFR-mutated lung cancer has evolved, with 3 strong options now available, including single-agent osimertinib and 2 combinations: osimertinib plus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results